Trial register facet
Trial records in atherosclerotic cardiovascular disease and cardiovascular risk reduction — page 3
71 records bearing on atherosclerotic cardiovascular disease and cardiovascular risk reduction.
Showing 0 records on this page
Records
71 documents · page 3 of 3
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SUSTAIN-6-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| LEADER-ELDERLYprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| EMBRACE-STEMI-DDIprogramme record | Exenatide | Phase 1 | Reported | Randomised crossover | — | 2016 | Very low |
| SUSTAIN-6-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| LEADER-BIOMARKERprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| EMBRACE-STEMI-PKprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2016 | Very low |
| SUSTAIN-6-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| EMBRACE-STEMI-RENAL-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2016 | Very low |
| LEADER-QOLprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| EMBRACE-STEMI-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2016 | Very low |
| ELIXA | Lixisenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 6,068 | 2015 | High |
| ELIXA-DDIprogramme record | Lixisenatide | Phase 1 | Reported | Randomised crossover | — | 2015 | Very low |
| ELIXA-HEPATIC-IMPprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2015 | Very low |
| ELIXA-RENAL-IMPprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2015 | Very low |
| ELIXA-PKprogramme record | Lixisenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2015 | Very low |
| TB4-PH1-CARDIAC | Thymosin beta-4 | Phase 1 | Reported | Phase 1 ascending dose | — | 2012 | Very low |
| TB4-PH1-CARDIAC-REGIONAL-CNprogramme record | Thymosin beta-4 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2012 | Very low |
| TB4-PH1-CARDIAC-QOLprogramme record | Thymosin beta-4 | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2012 | Very low |
| TB4-PH1-CARDIAC-BODY-COMPprogramme record | Thymosin beta-4 | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2012 | Very low |
| TB4-PH1-CARDIAC-REGIONAL-JPprogramme record | Thymosin beta-4 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2012 | Very low |
| SYNCHRONIZE-CVOT | Survodutide | Phase 3 | Ongoing | Event-driven cardiovascular outcome trial | — | — | Not rated |
| SYNCHRONIZE-CVOT-RENAL-IMPprogramme record | Survodutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| SYNCHRONIZE-CVOT-PKprogramme record | Survodutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
page 3 of 3